title: Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?
abstract: The present study focused on patients with cystic fibrosis (CF), who were on maintenance therapy with recombinant human deoxyribonuclease (rhDNase), with the aim of comparing efficacy and possible side effects of nebulisation of rhDNase when taken before bedtime with efficacy and side effects when taken after waking up. A randomised, double-blind, double-dummy, crossover study group was used. The inclusion criteria were as follows: 1) CF, 2) stable clinical condition and 3) rhDNase maintenance therapy. Patients in group I inhaled rhDNase before bedtime and a placebo after waking up in weeks 1-2. The protocol was reversed during weeks 3-4. Group II patients performed the reverse of this sequence. Patients continued with their daily routine sputum expectoration. The primary end-point was classified as the maximal instantaneous forced flow when 25% of the forced vital capacity remained to be exhaled (MEF(25%)). Pulmonary functions tests were performed on days 0, 7, 14, 21 and 28. At 1, 2, 3 and 4 weeks arterial oxygen saturation and cough frequency were measured during the night. A total of 24 patients completed the study. The mean (range) age of the patients was 13 (6-19) yrs. MEF(25%), taken to be the primary end-point, did not show a significant difference between nebulisation of rhDNase before bedtime compared with when taken after waking up. Nocturnal cough, oxygen saturation, and other secondary end-points were not significantly different between the two study periods. In conclusion, the present study found that it is equally effective and safe to nebulise recombinant human deoxyribonuclease before bedtime compared with when performed after waking up in children with cystic fibrosis, who are on maintenance treatment with recombinant human deoxyribonuclease.
authors.affiliation: Department of Paediatric Physiotherapy, Sophia Children's Hospital, Erasmus MC, Rotterdam, The Netherlands. l.vandergiessen@erasmusmc.nl
authors.forename: L J
authors.initials: LJ
authors.lastname: van der Giessen
authors.forename: R
authors.initials: R
authors.lastname: Gosselink
authors.forename: W C J
authors.initials: WC
authors.lastname: Hop
authors.forename: H A W M
authors.initials: HA
authors.lastname: Tiddens
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018592:Cross-Over Studies; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology*; D003850:Deoxyribonuclease I / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D010919:Placebos; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000737:chemistry; D013997:Time Factors
chemical_list: D010919:Placebos; D011994:Recombinant Proteins; D003850:Deoxyribonuclease I